Manish Trivedi, MD
Infectious Disease · Pomona, NJNPI 1760785414
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,963 of the $35,898 with a category attached, or 89.0%. AbbVie accounts for 94.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $12,831 and has fallen 76.9% since, to $2,964 in 2025. Among infectious disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $159.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$34K
- Melinta Therapeutics, LLC$542
- Merck$404
- Pfizer$176
- Insmed, Inc.$147
- Shionogi Inc$106
- plus $452 from 11 others
What the payments were for
- Speaking & faculty fees$31,96389%
- Travel & lodging$4771%
- Food & beverage$3,42710%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $34,070 |
| Melinta Therapeutics, LLC | 54 | $542 |
| Merck | 27 | $404 |
| Pfizer | 12 | $176 |
| Insmed, Inc. | 9 | $147 |
| Shionogi Inc | 6 | $106 |
| Paratek Pharmaceuticals, Inc. | 6 | $100 |
| Gilead | 6 | $79 |
| Cumberland Pharmaceuticals, Inc. | 4 | $54 |
| Viiv Healthcare Company | 3 | $51 |
| La Jolla Pharmaceutical Company | 2 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Vyera Pharmaceuticals, LLC | 2 | $24 |
| Cepheid | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Theratechnologies Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,898 in reported general payments places this provider in the 95th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 167 | $61,263 |
| ErtapenemErtapenem Sodium | 98 | $33,262 |
| CeftriaxoneCeftriaxone Sodium | 246 | $14,848 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 86 | $6,628 |
| Vancomycin Hcl | 25 | $963 |
| Sodium Chloride0.9 % Sodium Chloride | 210 | $765 |
| Cefepime Hcl | 27 | $640 |
| Cefazolin Sodium | 23 | $500 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Pomona
- Paras UdaniPomona$36K
- Keith GottesdienerRahway$2.1M
- Jihad SlimNewark$2.1M
- Maria SzabelaNewark$474K
- Ronald NahassHillsborough$213K
- Christopher LucastiSomers Point$112K
- Spartaco BellomoJersey City$111K
- Jack BoghossianBayonne$97K
- Adriana GrigoriuJersey City$89K
- Sukrut DwivediOakhurst$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.